Health Highlights: May 16, 2008
Post-Concussion Activity Levels Affect Recovery FDA Repeats Warning About Transplant Drugs Most U.S. Teen Girls Suffer Sexual Harassment: Study Scientific Laboratories Inc. Banned From Making, Distributing Drugs Texas Seafood Producer Ordered to Close, Recall Products Drug Shows Promise in Atrial Fibrillation Patients
Here are some of the latest health and medical news developments, compiled by editors of HealthDay:
Post-Concussion Activity Levels Affect Recovery
The activity level of athletes after they've suffered a concussion affects brain function and speed of recovery, says a U.S. study in the Journal of Athletic Training.
Athletes who engage in high levels of activity following a concussion showed impaired brain function, while those who engaged in moderate levels of activity had the best performance on brain function tests, the study found.
"We surmise that most athletes in the highest-intensity activity group probably experienced a less severe initial injury, but by continuing with high levels of activity, they began to exhibit similar symptoms to those who initially experienced a more severe concussion," researcher Jason P. Mihalik, a certified athletic trainer at the University of North Carolina, said in a prepared statement.
The study also found differences in recovery based on age and gender, which suggests that different post-concussion strategies may be needed for certain groups of athletes.
FDA Repeats Warning About Transplant Drugs
The organ transplant drugs CellCept and Myfortic can cause miscarriages and birth defects when used by pregnant women, the U.S. Food and Drug Administration reminded doctors Friday.
In an online notice to doctors posted Friday, the agency recommended "confirming that a pregnancy has not occurred and ensuring that patients use effective contraceptive measures," the Associated Press reported.
The drugs suppress the immune system in order to avoid organ rejection in transplant patients. Last October, the FDA added its most serious warning to CellCept and Myfortic after it received reports of miscarriages and infants born with ear and mouth defects after their mothers took CellCept.
Most of these cases occurred in mothers who took the drug before they knew they were pregnant, said the FDA, which noted that some of the women were taking the drugs for unapproved conditions such as lupus and rheumatoid arthritis, the AP reported.
Most U.S. Teen Girls Suffer Sexual Harassment: Study
About 90 percent of American teenage girls have suffered at least one incident of sexual harassment, suggests a study that included 600 girls, ages 12 to 18.
The researchers found 67 percent of the girls reported receiving unwanted romantic attention, 62 percent were exposed to demeaning gender-related comments, 58 percent were teased because of their appearance, 52 percent were subjected to unwanted physical contact, and 25 percent were bullied or threatened with harm by a male, United Press International reported.
In addition, 76 percent of the girls reported sexist comments on their athletic abilities, and 52 percent received discouraging gender-based comments about their math, science and computer abilities.
The findings were published in the May/June issue of the journal Child Development.
Scientific Laboratories Inc. Banned From Making, Distributing Drugs
Scientific Laboratories Inc. has been banned from making and distributing drug products until their manufacturing operations meet federal regulations and their products are approved, the U.S. Food and Drug Administration said Friday.
The company is a contract manufacturer and distributor of various prescription cough and cold products. A number of Scientific Laboratories' drugs "have not undergone FDA review for safety and efficacy and may pose potential health risks," Dr. Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, said in a prepared statement.
The unapproved new drugs manufactured and marketed by Scientific Laboratories as prescription cough and cold products include: B-Vex Suspension; Ben-Tann Suspension; D-Tann Suspension; D-Tann AT Suspension; D-Tann CT Suspension; D-Tann DM Suspension; D-Tann HC Suspension; Dur-Tann DM Suspension; Duratan DM Suspension; L-All 12 Suspension; Nazarin Liquid; and Nazarin HC Liquid.
Pharmacies should stop dispensing these products, and consumers with these products in their homes should talk to their health care provider about whether to stop using the products, the FDA said.
Texas Seafood Producer Ordered to Close, Recall Products
A seafood processing company in Texas has been ordered to close down and recall all products manufactured at its facility since 2007, the U.S. Food and Drug Administration said Friday.
Under a different name, Hope Food Supply Inc., of Pasadena, Texas, had made dried smoked catfish steaks and other smoked seafood products but was ordered to close until it developed and implemented an adequate Hazard Analysis and Critical Control Point (HACCP) plan for its products.
The company hasn't developed this plan and can't resume production until it's implemented an approved HACCP plan, the FDA said. This type of plan requires the company to identify all food safety hazards likely to occur with each type of seafood product they process and establish preventive measures to control those hazards.
Without such a plan, seafood products could contain potentially harmful bacteria that could cause serious illnesses in people.
Hope Food Supply's products have been distributed across the United States. Consumers should take any smoked seafood products to the place of purchase to determine if the products came from Hope Food Supply. If so, the products should be thrown away, the FDA said.
Consumers who have eaten Hope Food Supply dried smoked catfish or other smoked seafood products and have suffered adverse reactions should consult a health care professional.
Drug Shows Promise in Atrial Fibrillation Patients
The investigational drug Multaq (dronedarone) decreased the risk of cardiovascular hospitalization or death from any cause by 24 percent in patients with atrial fibrillation or atrial flutter, according to drug maker Sanofi-Aventis.
The findings were expected to be presented at a meeting of the Heart Rhythm Society, in San Francisco.
"Atrial fibrillation is a very common disease, and our prior treatment options have been focused only on symptom relief and a hope to not do harm, which has been the problem with prior antiarrhythmic drugs," Dr. Christopher Cannon, a senior investigator in the TIMI Study Group at Brigham and Women's Hospital in Boston, said in a prepared statement.
"Now with (this study) demonstrating a highly significant reduction in death or hospitalization, as well as a 45 percent reduction in arrhythmic death or 30 percent cardiovascular death, dronedarone may become an appropriate treatment option for atrial fibrillation," said Cannon, who was not involved in the study.
Atrial fibrillation affects about 2.5 million people in the United States and about 4.5 million people in the European Union.